Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. (March 2022)

• Record Type: Journal Article
• Authors: Villacampa, Guillermo; Tolosa, Pablo; Salvador, Fernando; Sánchez-Bayona, Rodrigo; Villanueva, Lorea; Dienstmann, Rodrigo; Ciruelos, Eva; Pascual, Tomas
• Is Part Of: Cancer treatment reviews. Volume 104(2022)
• Publication Date: 2022-03
• Subjects: Triple-negative -- Metastatic breast cancer -- anti-PD1/PD-L1 -- Immune checkpoint inhibitors -- Systematic review -- Meta-analysis; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2022.102352
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Immune checkpoint inhibitors improve PFS and shows better OS among the PD-L1 + population in first-line metastatic triple-negative breast cancer. In the PD-L1 + population, no relevant differences were observed according to taxane regimen used. Chemotherapy naïve patients obtained a larger benefit with immune checkpoint inhibitors. A slightly increase of adverse events were observed with the use of immune checkpoint inhibitors in combination with chemotherapy. Abstract: Introduction: The addition of immune checkpoint inhibitors (ICI) to chemotherapy (CT) has been one of the main clinical research endeavors over the last few years in patients with metastatic triple-negative breast cancer (TNBC). Recent randomized controlled trials (RCTs) have presented heterogeneous results that have elicited discussion in the oncology community. Here we conducted a systematic review and meta -analysis to evaluate this strategy. Material and methods: A systematic literature review was conducted to identify RCTs that evaluated the combination of ICI plus CT versus CT alone in untreated metastatic TNBC. Random effects models were used to estimate pooled hazard ratios (HR) and odds ratios with 95% confidence intervals (95 %CI). Results: A total of three RCTs including 2, 400 patients with TNBC met the eligibility criteria. Patients with PD-L1-positive tumors had a significantly better PFS with the addition of ICI (HR = 0.67; 95 %CI: 0.58–0.79) and a trend towards better OS (HR = 0.79; 95 %CI: 0.60–1.03), while no benefit was observed in patients with PD-L1-negative tumors. In the PD-L1-positive subgroup, no relevant differences were found according to taxane agent used, ECOG performance status or number of metastatic sites. However, CT naïve patients obtained a larger benefit with ICI (PFS HR = 0.53) than patients previously treated with CT in neoadjuvant/adjuvant setting (PFS HR = 0.81). The most frequent immune-related adverse events in patients receiving ICI were hypothyroidism (16%) and hyperthyroidism (4.9%). Conclusions: ICI plus CT improves PFS and OS in PD-L1-positive population. A greater benefit in CT naïve patients was observed for the PD-L1-positive population while no difference was observed between taxane regimes used.